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Cell therapy: a challenge 
of translational medicine 
Replacement of damaged organs, tissues, and 
cells is one of the fundamental objectives of 
modern medicine, and the last decades have 
witnessed spectacular advances in organ/tis-
sue transplantation and related disciplines (or-
gan preservation, immunosuppression, patient 
clitical care, etc). Within this field, cell therapy 
still remains in its initial stages of translation to 
medicine, although it is the area that should 
profit more of the numerous developments in 
cell biology occurred in recent years.  It is over 
forty years that cell therapy is applied routinely 
in hematology to replace bone marrow cells 
damaged by accidental irradiation, mutations, 
or cancer. There have been also clinical advan-
ces in cell therapy related with other areas of 
medicine such as skin or bone/cartilage repla-
cement and regeneration. However, it is in the 
neurological diseases where the promises of cell 
therapy have probably created the highest ex-
pectations, as the ability of regeneration of the 
mammalian central nervous system is null, or 
very low. In addition, neurological disorders, and 
particularly neurodegenerative diseases, have 
high individual, social, and economic costs, thus 
representing one of the major challenges of de-
veloped societies. 
Cell therapy in diseases 
of the central nervous 
system; introductory  
remarks
Many diseases of the central nervous sys-
tem (CNS) are a consequence of the acute or 
chronic loss of neurons and/or glial cells owing, 
among other causes, to degenerative, toxic, 
traumatic, ischemic or inflammatory aggressions. 
Therefore, the replacement of damaged cells by 
new ones has been considered as a potential 
therapeutic strategy in these CNS disorders. 
Neurologic cell-based therapy implies not only 
the transplantation of exogenous tissues to re-
pair or restore function (cell replacement), but 
also the use of cells for the delivery of trophic 
factors with a protective action on the neurons 
affected by the ongoing pathological processes 
(neuroprotection) (1-3). Routes of cell or tis-
sue administration include direct intracerebral 
grafting by open surgery or through stereotaxic 
needles, as well as intrathecal or intraventricu-
lar delivery. Systemic intravascular (arterial or 
venous) injections are used in some cases and 
migration of the putative therapeutic cells to 
the site of lesion has been reported. Another 
plausible form of cell therapy is the activation 
of pre-existing neuronal precursors located in 
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neurogenic centers (i.e. the subventricular zone 
of the lateral ventricles or the dentate gyrus of 
the hippocampus) that could migrate and di-
fferentiate to replace destroyed cells in some 
parts of the brain. This possibility is speculative 
at present and based solely on preliminary ex-
perimental observations (4, 5).
In theory, the ultimate goal of neurologic cell 
therapy is the histological and functional integra-
tion of grafts within the neighboring brain pa-
renchyma. In this regard, synaptic connections 
between grafted neurons and the host tissue 
have been described in experimental studies. 
However, it has become evident that physiolo-
gical restoration of the intricate synaptic circuits 
of the brain cannot be achieved through the cell 
replacement protocols currently used to treat 
CNS disorders. In contrast, the beneficial effects 
of transplants are, in most cases, a consequence 
of gross anatomical or neurochemical modifi-
cations in the recipient organ. For instance, the 
amelioration of parkinsonism after intrastriatal 
grafting of dopaminergic tissue is due to the tonic 
release of dopamine and/or trophic factors from 
grafted cells which, respectively, activate dopami-
ne receptors in neighboring neurons and induce 
sprouting of the dopaminergic nigrostriatal fi-
bers in the host brain. Therefore, the best results 
of cell therapy are obtained in CNS disorders, 
such as Parkinson’s disease (PD), with relatively 
focalized lesions and affecting diffuse synaptic 
circuits in which pre-post synaptic specification 
is not an absolute requisite for the restoration 
of function. At present, it is difficult to envisage 
how therapies based on cell replacement or the 
activation of preexisting neurons could restore 
the delicate cortical and hippocampal synaptic 
circuits underlying memory storage and retrie-
val extensively damaged in Alzheimer’s disease 
patients. Other limitations of cell therapy derive 
from the scarcity of cells/tissues that are appro-
priate for transplantation. Although autogra-
fts can be performed in some cases, the most 
frequently used clinical protocols are based on 
allo- or even xenografts, thus requiring immuno-
suppression treatment. Allotransplants are also 
rendered difficult because the use of tissue from 
human donors (i.e. human fetuses or embryos) 
raises numerous legal and ethical issues. 
Despite the limitations described above, cell 
therapies have been successfully applied to the 
treatment of neurological diseases for over two 
decades. The pioneer studies, designed to treat 
advanced PD patients with excellent results in 
some cases, stimulated the development of the 
field and were followed by a great deal of ex-
perimental and clinical work. These studies have 
boosted the development of animal models of 
numerous CNS diseases and the appearance 
of well-defined clinical protocols to evaluate 
disease progression. Nevertheless, the initial 
enthusiasm derived from the results of open 
trials has been tempered by the less spectacular 
clinical outcomes of double-blind and placebo-
controlled studies performed with large patient 
cohorts.   Recently there has been, however, re-
newed interest in the cell therapy field due to 
the appearance of new cell sources, particularly 
stem cells, with potential clinical applicability. Cu-
rrently, there are numerous ongoing experimen-
tal and clinical transplantation studies designed 
to test the therapeutic efficacy of several cell 
types in a variety of neurological diseases, such 
as PD, Huntington’s disease (HD), amyotrophic 
lateral sclerosis (ALS), stroke, and spinal cord in-
jury (SCI), among others.
This chapter aims to provide a general over-
view of the current status of cell therapies 
applied to CNS disorders. After a concise up-
date of the preclinical knowledge available, the 
studies and techniques that have already resul-
ted in clinical application are discussed in more 
detail. In this respect, the chapter’s main focus is 
PD, a prototypical neurodegenerative disease in 
which the most solid and promising conceptual 
and technological advances in neurologic cell 
therapy have been tested. In addition, recent 
developments related with cell therapy applied 
to other CNS disorders (i.e. HD, ALS, stroke, 
or SCI) are briefly addressed. The chapter ends 
with a concluding summary and look at future 
perspectives in the field.
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Cell therapy in Parkinson’s 
disease
Pathophysiology and novel 
therapeutic strategies in 
Parkinson’s disease
Parkinson’s disease (PD) is a progressive neu-
rodegenerative disorder of unknown etiology. 
Although several genetic forms have been des-
cribed (6) the majority of cases are sporadic and 
unrelated to familial traits. PD is a major health 
problem in developed countries, as it affects to 
100-300 subjects per 100,000 inhabitants and up 
to 3% of people older than 65 (7, 8). The motor 
symptoms of PD (tremor, bradykinesia/hypokine-
sia, rigidity, and alterations of gait and posture) 
are due to the progressive loss of dopaminergic 
neurons in the substantia nigra (SN) and their 
projections to the striatum (Figure 1). The dege-
nerative process also affects other areas of the 
CNS and the peripheral autonomic nervous 
system, thus causing several non-motor symp-
toms, such as depression, cognitive impairment, 
and autonomic dysregulation (9). Although the 
progressive neuronal loss is a common feature 
of all neurodegenerative diseases, a typical pa-
thological hallmark of PD is the appearance of 
cytoplasmic inclusions, called Lewy bodies, con-
taining synuclein and ubiquitin among other pro-
teins. The mechanism of neuronal death in PD is 
likely multi-factorial, involving a cascade of events 
among which cellular oxidative damage appears 
to have a prominent role (Figure 1). Selective de-
crease of reduced glutathatione, mitochondrial 
complex I activity, and reactive oxygen species 
(ROS)-destroying enzymes, or elevated con-
centrations of iron, which can act as a catalyst 
for detrimental oxidative reactions, have been 
reported within the parkinsonian SN. Similarly, 
there is evidence of oxidative damage to lipids, 
proteins and DNA in the brains and leukocytes 
of PD patients. Inflammatory-related events, such 
as nitric oxide-derived reactive species produced 
by glial inducible nitric oxide synthase, appear also 
to participate in SN dopaminergic degeneration 
(10). Besides mitochondrial dysfunction and the 
oxidative or inflammatory stresses, alteration of 
protein-degrading mechanisms at the proteaso-
me is an additional factor that participates in 
PD initiation and/or progression. For example, 
mutations in α-synuclein (a presynaptic protein 
of unknown function that is deposited in Lewy 
bodies) or in parkin (a ubiquitin ligase necessary 
for protein identification by the proteasome) are 
responsible for some forms of genetic PD (6). 
Figura 1. Dopaminergic nigrostriatal pathway. A) Mouse dopaminergic nigrostriatal neurons and fibers 
stained using antibodies anti tyroxine hydroxylase. SN, substantia nigra; St, Striatum. B) Schematic repre-
sentation of a dopaminergic presynaptic terminal. Uptake of dopamine (DA) and its metabolization to 
dihydroxyphenyl acetic acid (DOPAC) and hydrogen peroxide (H2O2) are illustrated. DAT, dopamine 
transporter ; MAO, monoamine oxidase.  
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PD treatment relies mainly on L-dopa, a drug 
that is converted to dopamine in neuronal so-
mata and presynaptic terminals. L-dopa is nor-
mally complemented with the administration 
of dopamine receptor agonists or inhibitors 
of dopamine-degrading enzymes (monoamine 
oxidase and catechol-o-methyl transferase). 
Patients who develop disabling motor com-
plications (motor fluctuations and dyskinesias) 
or drug-resistant tremor can be candidates for 
surgical implantation of electrodes for electrical 
stimulation, these normally being placed at the 
subthalamic nuclei. This methodology, consisting 
of the application of high frequency (> 100 
Hz) electrical pulses to inhibit neuronal activi-
ty, can correct the alterations of basal ganglia 
circuits in the parkinsonian brain. Although the 
current pharmacological and surgical therapies 
are symptomatically effective, their long-term 
utility is limited because they do not halt the 
disease progression (11). Therefore, there is a 
need for neuroprotective and/or neurorestora-
tive therapies capable of arresting or reversing 
the neurodegenerative process. Dopamine cell 
replacement and the intracerebral administra-
tion of trophic factors are cell-based promising 
therapeutic approaches currently subjected to 
intense basic research and clinical evaluation.  
Transplantation of dopamine-
secreting cells. Preclinical 
studies
Mammalian models of Parkinson’s disease
Development of research on CNS cell thera-
py depends on the existence of animal models 
of the neurological diseases, where the effecti-
veness, advantages, and limitations of the various 
therapeutic approaches can be tested experi-
mentally. A brief description of the mammalian 
models of PD available is given below.
A commonly used PD animal model is the 
hemiparkinsonian rat, generated by unilateral 
stereotaxic injections of 6-hydroxydopamine 
(6-OHDA) either into the SN, the neighboring 
medial forebrain bundle, or the striatum. In all 
cases the drug is metabolically converted to do-
pamine and generates H2O2, which subsequently 
kills the dopaminergic nigrostriatal neurons due 
to oxidative stress (Figure 2). Unilateral destruc-
tion of the dopaminergic nigrostriatal neurons 
produces a spontaneous rotational behavior 
towards the side of the lesion (greatly exacer-
bated by administration of D-amphetamine) 
that is easily monitored with a rotameter.  As 
the number of rotations is proportional to the 
degree of SN lesion (and to the extension of 
striatal dopaminergic denervation) this model 
permits the experimenter to test the recovery 
of the syndrome after striatal transplantation of 
dopamine (and/or trophic factor)-releasing cells 
(Figure 2) (12). The 6-OHDA model has, howe-
ver, numerous limitations since it is generated 
by acute oxidative damage to SN dopaminergic 
neurons, a phenomenon quite different from 
the chronic and progressive death of this neu-
ronal population characteristic of PD. Moreover, 
the direct mesencephalic injection of 6-OHDA 
makes it difficult to obtain animals with partial 
lesions, which are required to test neuroprotec-
tive therapies based on the trophic action of 
the transplanted cells on nigrostriatal neurons 
spared by the lesions or still unaffected by the 
ongoing neurodegenerative process. In the last 
few years there have been several attempts 
to generate chronic rat PD models, although 
their feasibility and reproducibility are still under 
scrutiny.  Chronic intravenous or subcutaneous 
administration of rotenone (a membrane-per-
meable inhibitor of mitochondrial complex I) 
seems to produce bilateral destruction of do-
paminergic SN neurons with Lewy body-like 
cytoplasmic inclusions. Similar results have also 
been reported after chronic administration of 
proteasome inhibitors. Unfortunately, the validi-
ty and reproducibility of this model (that initia-
lly raised great expectations) is being seriously 
questioned (10, 13).
The monkey model of PD is also broadly 
used owing, among other reasons, to the need 
for testing in non-human primates most of the 
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cell therapy procedures destined for clinical use. 
Monkeys are chronically treated by subcuta-
neous injections of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a drug converted 
in the primate brain to 1-methyl-4-phenylpyri-
dinium ion (MPP+) which, in turn, is taken up 
selectively by dopaminergic neurons via the 
dopamine transporter (Figure 1). As MPP+ is 
a potent mitochondrial complex I inhibitor, its 
chronic application leads to progressive dopa-
minergic cell death. MPTP has similar actions in 
mice (see below) but is ineffective in rats since 
they do not express the enzymes required to 
convert MPTP into MPP+. In primates (monkey 
and human) MPTP produces a bilateral parkin-
sonian syndrome with motor features similar 
to those present in sporadic PD (10, 14). The 
objectives of experimental cell therapy in par-
kinsonian monkeys are similar to those descri-
bed above for the rat. Dopamine- or trophic 
factor-releasing cells are normally deposited ste-
reotaxically in the striatum (normally at several 
locations in the putamen) and clinical recovery 
is monitored with ad hoc behavioral tests. The 
MPTP monkey is particularly useful to perform 
unilateral striatal transplants since the contrala-
teral striatum (injected with saline solution) can 
be used as control. In these cases, the success 
of the procedure results in unilateral histological 
and clinical recovery, with the animals behaving 
in a hemiparkinsonian manner hence showing 
a typical rotational behavior towards the side 
contralateral to the transplant (15). 
Systemic administration of MPTP in mice 
produces bilateral destruction of dopaminergic 
nigrostriatal neurons (10, 16, 17). The parkin-
Nigrostriatal denervation in the hemiparkinsonian rat Striatal reinervation after CB grafting
Figura 2. Hemiparkinsonian rat model and intrastriatal grafting of dopaminergic cells. A) Coronal sec-
tions at the level of the striatum (St) and the mesencephalon (SN, substantia nigra; VTA, ventral tegmen-
tal area) showing the normal (left) and denervated (right) nigrostriatal pathway. B) Striatal dopaminergic 
reinnervation after transplantation of carotid body glomus cells (g, graft).
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sonian syndrome in mice is less amenable for 
behavioral analysis than the syndrome in the rat; 
however mice are sometimes chosen because 
MPTP administration requires no surgery and, 
as in the case of primates, if unilateral transplan-
tation is performed the contralateral side can 
be used as an internal control. In addition, sus-
ceptibility to MPTP-derived toxicity can be stu-
died in the numerous genetically modified mice 
strains available. An acute MPTP mice model is 
normally generated by subcutaneous injections 
(single or distributed over 12-24 h) of the drug. 
Chronic models, based on the continuous de-
livery of MPTP using subcutaneous pumps or 
repeated injections, are being assayed in several 
laboratories but results differ among the various 
groups and animals strains.
There are several mouse genetic models in 
which some of the genes altered in familial PD 
(i.e. α-synuclein or parkin) have been transgeni-
cally overexpressed in an attempt to reproduce 
the disease. So far, none of these genetically mo-
dified animals exhibit clear histological, neuroche-
mical or behavioral signs of parkinsonism. Ano-
ther PD mouse model is the one obtained after 
genetic disruption of the glial cell line-derived 
neurotrophic factor (GDNF) signaling pathway. 
GDNF is the most representative member of 
a family of trophic factors (called dopamino-
trophic factors) that promote the in vivo and 
in vitro survival of dopaminergic neurons (see 
below). GDNF null animals die at early neonatal 
stages due to kidney agenesia and alterations of 
the enteric nervous system, although in these 
animals both the SN and the striatum are nor-
mal. In adult life, the overall GDNF expression in 
the central nervous system decreases drastically, 
although high levels of GDNF are maintained in 
some striatal neurons and glial cells, possibly as 
a mechanism to aid trophic maintenance of the 
nigrostriatal pathway.  Heterozygous GDNF+/- 
animals develop normally, although it has been 
reported that they show a mild reduction of the 
dopaminergic neuronal pool at advanced age. 
Thus, it seems that abolition of GDNF expres-
sion (or function) in the adult mouse could ser-
ve as a good PD mouse model. Conflicting re-
sults have recently been reported regarding the 
effect of c-ret (a transmembrane component of 
the GDNF receptor) knock-out in adult life (18, 
19). The conditional GDNF null mouse recently 
generated in our laboratory has demonstrated 
that striatal GDNF production is absolutely ne-
cessary for the survival of adult mesencephalic 
dopaminergic neurons. These animals show an 
extensive loss of cells in SN and VTA as well as 
in the Locus coeruleus.  They also have a clear 
akinetic syndrome that ameliorates after L-dopa 
administration (19b).  
Preclinical transplantation studies
The first cell therapy studies in animal models 
of PD were performed in the late 1970s in rats 
using fetal rat dopamine-containing neurons as 
donors with the aim of restoring striatal dopa-
mine levels. In these investigations, improvement 
of the functional deficits in parkinsonian animals 
was paralleled by the survival of intrastriatal gra-
fts and axonal outgrowth (20, 21). After this pio-
neer work, numerous studies have been perfor-
med in the last 25 years in an effort to address 
the following main objectives: 
 I. To establish the effectiveness of different ty-
pes of donor tissue on recovery from the 
parkinsonian syndrome. 
 II. To test the survival of the transplanted tissue 
and its histological integration within the host 
striatal parenchyma.
 III. To evaluate electrophysiological and neuro-
chemical activity in grafts and the establish-
ment of functional connections (synapses) 
between the graft and the host brain. 
IV. To determine whether immunosuppression 
facilitates long-lasting cross-species trans-
plantation of neural and non-neural tissues. 
After the initial transplantation of mesen-
cephalic tissue from rat embryo to rats, a step 
further was the transplantation of mesencepha-
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lic dopaminergic neurons, taken from mouse 
embryos or human fetuses, to the dopaminer-
gically denervated neostriatum of recipient rats, 
and the use of primates with MPTP-induced 
Parkinson-like syndrome as graft receptors (22). 
At the same time, adrenal chromaffin cells were 
used as an alternative dopamine source in PD 
animal models, from rats to primates, although 
with poorer results than those obtained using 
embryonic or fetal dopamine neurons (23). 
In parallel with these studies there have been 
several reports from groups using porcine me-
sencephalic neurons with good results  (24). Si-
milarly, tissues in the peripheral nervous system, 
other than the adrenal medulla, have been used. 
In those studies, transplants of sympathetic neu-
rons from the superior cervical ganglion were 
performed in experimental animal models as 
well as in humans (25). 
Among the most promising new experimen-
tal approaches developed within the last few 
years are the transplantation of retinal pigment 
epithelial cells and of carotid body tissue. In 
the first case, stereotaxic intrastriatal implan-
tation of human retinal pigment epithelial cells 
attached to gelatin microcarriers in rodent and 
non-human primate models of PD produced 
long-term amelioration of motor and behavio-
ral deficits, with histological and PET evidence of 
cell survival without immunosuppression (26). 
In the second case, the autotransplantation of 
dopaminergic carotid body (CB) cell aggrega-
tes was able to effect notable histological and 
functional recovery in parkinsonian rats (27, 28) 
and MPTP-treated monkeys (15). The CB is a 
tissue particularly attractive for antiparkinsonian 
cell therapy because it combines the properties 
necessary for dopamine cell replacement and 
for neuroprotection. The CB contains neural 
crest-derived dopaminergic glomus cells, which 
function as arterial oxygen sensors and relea-
se large amounts of dopamine in response to 
hypoxia. Long-term recovery of parkinsonian 
animals after intrastriatal CB grafting is induced 
not only by the release of dopamine, but also 
through a trophic effect on nigrostriatal neu-
rons. In fact, adult rodent CB cells express much 
higher GDNF levels than any other paraneural 
cells studied (adrenal medulla, superior cervical 
ganglion, Zuckerland’s organ and PC12). Mo-
reover, GDNF expression by CB glomus cells is 
maintained after intrastriatal grafting and in CBs 
of aged or MPTP-treated animals (29) (Figure 
3). Thus, glomus cells appear to be miniaturized 
biological pumps useful for the local delivery of 
GDNF and possibly other trophic factors.  
Besides the transplantation of dopamine-
producing cells, other experimental strategies 
have been designed to directly increase the 
striatal concentration of trophic factors that 
could eventually induce regeneration of the 
dopaminergic nigrostriatal pathway. Among 
these studies Sertoli cells from the testis, am-
niotic epithelial cells or genetically modified 
cells overexpressing trophic factors have been 
used. Some of these trophic factor-producing 
cell types have been assayed in conjunction 
with dopamine releasing cells (i.e. cotransplan-
tation of peripheral nerve plus adrenal medu-
lla, and Sertoli or CB cells plus ventral mesen-
cephalic neurons) (30). 
After more than 20 years of preclinical re-
search in antiparkinsonian cell therapy, the stu-
dies performed can be retrospectively classified 
into three major groups:
 I. Intrastriatal transplantation of heterologous 
dopaminergic neurons to compensate for 
the loss of intrinsic dopaminergic fibers. For 
these studies, fetal mesencephalic neurons 
were normally used and the establishment 
of synaptic connections between the graft 
and host neurons was considered a good 
indication of graft survival and integration in 
the recipient brain. More recently, fetal me-
sencephalic neurons are being substituted by 
stem cell-derived dopaminergic neurons (see 
Section 3.2). 
 II. Intrastriatal transplantation of dopamine-
releasing cells (adrenal chromaffin, retinal or 
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carotid body cells) with the sole objective of 
increasing the average level of dopamine in 
the striatal parenchyma. Functional connec-
tions between the graft and host tissues were 
not expected. 
III. Intrastriatal delivery of cells releasing trophic 
factors (carotid body, retinal cells, Sertoli or 
amniotic epithelial cells or genetically modi-
fied cells), to encourage striatal reinnervation 
through sprouting of the intrinsic nigrostriatal 
neurons.  
Over the years, interest has shifted from pro-
cedures that could be included in categories i/ii 
to those included in category iii. In the initial sta-
ges, the limiting factors in cell therapy research 
were graft survival and accessibility to an abun-
dant dopaminergic neuronal source. Currently, 
it is considered more important to determine 
the mechanisms of action of the transplants to 
help better define the type of patient that could 
eventually benefit from cell therapy.
Current developments using stem cells 
Embryonic stem (ES) cells are generally thought 
to offer a promising source of dopaminergic neu-
rons suitable for PD cell therapy. They are charac-
terized by a high proliferation rate and the po-
tential to give rise in vitro to any cell type of the 
adult organism (2). In recent years, the differentia-
tion of mouse embryonic stem cells into dopa-
minergic neurons has been repeatedly obtained 
in different laboratories following two different 
approaches. One involves the co-culture of ES 
cells with stromal feeder cells (PA6, MS5) that fa-
cilitates the induction of the neural fate. Another 
approach implies a five-stage method based on 
the formation of a three-germ layer structure, the 
embryoid body, from which neural cells can be 
selected. In both protocols, neural progenitor cells 
Intrastriatally grafted carotid body cells Carotid body cells in situ
Figura 3. Maintenance of carotid body glomus cell phenotype in situ (right) and several weeks after 
intrastriatal transplantation (left). Immunocytochemical staining using anti tyroxine hydroxylase antibo-
dies (brown-yellow) and X-galactosidase (green). The X-gal signal indicates that the GDNF promoter is 
active in these dopaminergic cells. See reference (29) for further details.  
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can be expanded and induction to the midbrain 
dopamine fate can be favoured by exposing the 
cells to appropriate morphogenetic factors (31, 
32). Neuronal differentiation is normally triggered 
by mitogen withdrawal, and the dopaminergic 
phenotype is normally demonstrated by identifi-
cation of the cells with markers such as tyrosine 
hydroxylase and the dopamine transporter (Figu-
re 4). Embryonic stem cell-derived dopaminergic 
neurons are normally obtained from established 
ES cell lines, however, dopaminergic neurons have 
also been derived from embryos obtained by nu-
clear transfer or from induced pluripotent stem 
cells (iPSC). 
Striatal transplantation of previously specified 
midbrain ES cell-derived neural progenitors cells 
has been reported to provide surviving dopa-
minergic neurons in the host brain and render 
histological, neurochemical and behavioral re-
covery of hemiparkinsonian rats (33, 34) (Figu-
re 4). If ES cells are genetically manipulated to 
overexpress the nurr-1 gene, dopaminergic neu-
ronal differentiation is markedly increased and, 
subsequently, a higher yield of surviving dopa-
minergic neurons is achieved upon grafting (33). 
One major drawback of ES cell-based therapy 
is tumor generation, however this possibility is 
greatly diminished with appropriate differentia-
tion procedures that eliminate all proliferative ES 
cells from the transplanted preparation. Several 
recent studies performed in non-human primate 
and human ES cells have demonstrated the abili-
ty of these cells to differentiate into dopaminer-
gic neurons. However, survival of transplanted 
dopaminergic neurons, an absence of prolifera-
tive cells in the grafts, and consistent behavioral 
recovery are issues that seriously compromise 
the clinical applicability of human ES cell-derived 
neurons. Identification of key factors determi-
ning the survival of human ES cell-derived do-
paminergic neurons is an active field of research 
for regenerative medicine (35).
Neural stem cells derived from fetal or adult 
brain have been shown to differentiate into 
dopaminergic neurons, although the yield is re-
latively poor due to their limited capacity for 
proliferation and because of their preferential 
glial differentiation. Different factors have been 
used to increase the dopaminergic differentia-
tion of neural stem cells with relatively modest 
success, although good results are beginning to 
be reported by some laboratories (35b). Bone 
marrow stromal cells and umbilical stem cells 
are also attractive sources of multipotent stem/
progenitor cells, currently subjected to intense 
research, that could eventually be used for au-
tologous transplants. However, the ability for do-
paminergic differentiation of these cells is quite 
limited. Neural crest-derived progenitors have 
also been recently described in the carotid body, 
which permit the adaptive growth of this organ 
in chronic hypoxia. In vitro, these progenitors can 
differentiate to dopamine and GDNF producing 
cells, hence they could be used for transplan-
tation studies in PD (35c). In summary, several 
critical challenges need to be overcome befo-
re fetal, adult or autologous stem cells can be 
brought into the clinical field to treat PD (35).
Transplantation of dopamine-
secreting cells. Clinical studies
General overview 
Transplantation of dopamine-secreting cells in 
advanced PD patients was initiated in the mid 
1980s. A summary of the transplantation pro-
cedures, with indication of the donor tissue and 
current status of the technique, is given in Table 
1. Despite the highly variable clinical outcomes 
of these studies, with excellent results reported 
in selected patients but only modest effects in 
most cases, the overall benefit experienced by 
the patients stimulated further research and cli-
nical tests. Clinical trials resulting in a higher im-
pact have been those employing adrenal medu-
lla or mesencephalic neurons as donor tissues. 
The first stereotaxic intrastriatal implantation 
of autologous adrenal medulla on four patients 
was performed, with modest results, by the Lund 
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group in 1985 (36). In 1987, a Mexican group re-
ported excellent clinical results (not confirmed 
by others) after transplantation by open surgery 
of adrenal tissue into a cavity made in the cauda-
te nucleus (37). These pioneer trials were soon 
followed by numerous studies in several hospi-
tals all over the world. These studies differed in 
the surgical approach (open versus stereotaxic) 
as well as in the procedures followed for adre-
nalectomy and the treatment given to the cells 
prior to transplantation. All studies performed 
were open, with few patients (3 to 20) and wi-
thout blind evaluation. In most cases the clinical 
efficacy of adrenal medulla autografts was very 
modest with a lack of neurochemical improve-
ment based on positron emission tomography 
Embryonic stem cells Neural precursor cells Dopaminergic neurons
Figura 4. In vitro differentiation of dopaminergic neurons from embryonic stem (ES) cells. A) Left, Colonies 
of mouse ES cells. Undifferentiated state is proved by Oct-4 staining. Calibration bars: 100 μm and 50 μm, 
in phase contrast and immunostaining, respectively. Center, Monolayer of ES cells-derived neural precur-
sors. Neural identity is proved by nestin staining on cells adopting typical rosette disposition. Calibration 
bars: 100 μm and 50 μm, in phase contrast and immunostaining, respectively. Right, ES cells-derived dopa-
minergic neurons (tyroxine hydroxylase,TH +). Calibration bar: 100 μm. 4´-6-diamidino-2-phenylindole 
(Dapi) shows nuclear counterstaining. B) Left. Photograph of the transplanted rat brain illustrating the 
localization of the graft in the striatum. The inset shows the dopaminergic identity (TH+) of the ES cells-
derived grafted neurons. Calibration bars: 500 μm and 200 μm (inset). Right. Schematic representation 
of the rotational behavior of hemiparkinsonian rats non-transplanted (red) and transplanted (green) with 
ES cells-derived dopaminergic neurons. See further details in the text and reference (33).
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(PET). Postmortem analyses have demonstrated 
an almost complete absence of chromaffin cells 
at the transplanted sites.  Several groups have 
reported that the viability of adrenal medulla 
grafts and their clinical efficacy increased if the 
cells were treated with trophic factors or co-
transplanted with other tissues (i.e. peripheral 
nerve) (38). The transplantation of adrenal tis-
sue to treat PD has, however, been abandoned 
due among other factors to the relatively high 
morbidity/mortality associated with the dual 
(abdominal and cranial) surgery and the deve-
lopment of other therapeutic approaches. The 
most compelling alternative to adrenal autogra-
fts is the transplantation of fetal mesencephalic 
neurons (see below), a technology that has do-
minated the clinical trials on cell therapy applied 
to PD patients for the last 15-20 years. 
Transplantation of fetal mesencephalic 
neurons 
The first intrastriatal transplants of human 
fetal mesencephalic tissue in PD patients were 
carried out by the Lund group between 1989 
and 1991, stimulated by the good results obtai-
ned with the same methodology in preclinical 
studies . Since some patients treated with fetal 
cells showed long lasting clinical improvement, 
this methodology was extended to other labo-
ratories. In most cases the technique used was 
the bilateral stereotaxic implantation of disper-
sed cells or tissue fragments in the caudate/
putamen. It is believed that this technique has 
been applied in open trials to several hundred 
patients although only about 50 have been ca-
refully evaluated in the scientific literature (see 
Tabla 1. Transplantation procedures in patients with Parkinson’s disease
Tissue Type of 
transplantation1
First 
report2
Spread  
of the technique
Level  
of development  
& current status
Adrenal medulla Autologous (36) Worldwide Abandoned
Homologous  
(human fetal)
(37) Single or few centers Abandoned
Adrenal medulla & 
peripheral nerve
Autologous (38) Single or few centers Abandoned
Mesencephalic tissue Homologous  
(human fetal)
(39) Worldwide Phase III studies3 in 
progress
Heterologous  
(porcine embryonic)
(40) Single or few centers Phase III study3 in 
progress
Retinal pigment 
epithelial cells
Homologous (post-
mortem eye donors)
(41) Single or few centers Phase III study3 in 
progress
Carotid body cells Autologous (42) Single or few centers Phase II clinical and 
PET study completed
Sympathetic ganglion 
cells
Autologous (43) Single or few centers Open-label series
1 Type of transplantation. Autologous: transplantation of tissue obtained from the same patient. Homologous: donor tissue obtained from other 
individuals of the same species. Heterologous: donor tissue obtained from individuals of different species. 2 First report. Refers to the first full 
publications of outcomes in patients. 3 Phase III studies refer to double-blind placebo-controlled trials.
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summary in Table 2). Although the transplanta-
tion methodology differs in the age and number 
of donor fetuses, the preparation, storage and 
dissociation of the tissue, and the protocol of 
immunosuppression used, the clinical evaluation 
of these patients has been more homogeneous 
than in the case of adrenal transplants. Patient 
evaluation was generally done with the Unified 
Parkinson’s Disease Rating Scale (UPDRS) and 
most assays followed the Core Assessment Pro-
gram for Intracerebral Transplantations (CAPIT) 
protocols (60). In the following sections we 
summarize the clinical results and other rele-
vant features of the main open studies and of 
the two double-blind, placebo-controlled, trials 
completed in recent years. 
Tabla 2. Methodology of the main open-label trials on human fetal mesencephalic transplants  
(see clinical outcomes in the text)
Country 
(city)
Ref. n Donors Graft type/ 
technique
Location  
of implants
IMS Clinic  
al follow-
up
PET1 Necropsy2
N.o per 
hemisphere
Age
Sweden 
(Lund)
(39, 44) 2 3-4 7-9 w Cells 
Stereotaxic
C + P Unilateral 6 m 18 m Yes (–) No
(45-47) 2 3-4 6-7 w Cells 
Stereotaxic
P Unilateral 6 m 3 y Yes (++) No
(48) 23 3-4 6-8 w Cells 
Stereotaxic
C + P Bilateral 12 m 2 y Yes (++) No
USA  
(Denver)
(49, 50) 7 1 7-8 w Cells or 
strands of 
tissue/ 
Stereotaxic
C + P 
P
Unilateral (2)
Bilateral (5)
6 m (4)
No (3)
4 y Yes (+) (1)
(–) (6)
No
USA  
(New 
Haven)
(51) 4 1 7-11 w Tissue/ 
Stereotaxic
C Unilateral 6 m 18 m Yes (+) (1) Yes (+/–) (1)
USA  
(Tampa/ 
New York/
Chicago)
(52-54) 6 3-4 6-9 w Tissue/ 
Stereotaxic
P Bilateral (6-8 
tracks/side)
6 m 2 y Yes (++) Yes (+++) (2)
France  
(Créteil)
(55-57) 5 2-3 6-9 w Cells 
Stereotaxic
C + P 
P
Unilateral (4)
Unilateral (1)
6 m 1-3 y Yes (++) No
Spain  
(Madrid)
(58) 10 1 6-15 w Tissue/ 
Open 
surgery
C Unilateral Chronic 5 y No No
USA  
(Los Angeles)
(59) 13 1 (6) 
≥ 2 (7)
6-9 w Tissue/ 
Stereotaxic
P Bilateral 18 m 6 m Yes No
Ref. (references): Publications where the results appeared. n: number of patients operated in the different trials. In other columns 
the number of patients is given between parentheses. Location of implants: C: caudate. P: putamen. IMS: immunosuppression. 
Other notations: w: weeks. m: months. y: years.
1 18F-dopa PET. Yes: at least some patients were studied. (−): no significant changes; lesser (+) or greater (++) increase in 18F-
dopa uptake. 2 Necropsy. Yes: at least some patients were studied. Uncertain (+/-), minor (+), moderate (++), or major (+++) 
graft survival and integration. 3 Two patients with MPTP-induced parkinsonism. 
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Clinical outcome. Open studies
The main methodological features of the 
open clinical studies performed with heterolo-
gous implantation of mesencephalic neurons in 
PD patients are summarized in Table 2.  In most 
trials the patients (between 2 and 13) suffered 
advanced PD with motor complications, and 
one study included two cases of MPTP-induced 
parkinsonism. The surgical procedures are varia-
ble, with uni- or bilateral caudate and /or puta-
minal implantations. The clinical follow-up of the 
patients varied between 6 months and 5 years 
and in most cases included neurochemical eva-
luation with [18F]-dopa PET analyses. Despite the 
methodological differences, all studies reported 
some degree of motor improvement in most 
Tabla 3. Methodology of the two double-blind placebo-controlled studies  
on human fetal mesencephalic transplants (see clinical outcomes in the text)
Double-blind placebo-
controlled trials
Denver/New York Group (61) New York/Chicago/Tampa Group (62)
Patients Transplant group: 20  (≤ 60 yrs: 10; 
> 60: 10)
Placebo group: 20 (≤ 60 yrs.: 11; > 
60: 9 )
Transplant group: 23 (1 donor: 11; 4 donors: 12)
Placebo group: 11
Follow-up 1 year 2 years
Loss of follow-up 1 (transplant group) 3 (group not specified)
Primary outcome Subjective global self-rating of change
(scale from -3 to +3) 
Change in UPDRS III
Donors:
• N.o/hemisphere
• Age
2
7-8 weeks
1 (11 patients); 4 (12 patients)
6-9 weeks
Graft type Strands of tissue
(cultured up to 4 weeks)
Fragments of tissue
(stored in cool hibernation medium up to 2 days)
Surgical technique Stereotaxic (bilateral in one stage)
2 twist-drill holes per side
Stereotaxic (bilateral in two stages)
1 burr hole per side
Location of implants Putamen bilateral (4 tracks per side; 
tissue deposited continuously)
Posterior putamen bilateral (8 tracks per side; 
4 deposits per track)
Immunosuppression No Cyclosporine during 6 months
18F-dopa PET One year after surgery:
• mean increase in uptake (− in 3 
patients)
• difference to placebo group
• no difference in ≤ 60 / > 60 years 
groups 
One and two years after surgery:
• mean increase in uptake
• difference to placebo group
• trend to a greater increase in the 4 donors 
group
Necropsy1 2 patients (> 60 years): ++
 
2 patients (1 donor/side): ++
2 patients (4 donors/side): +++
III: motor sub-scale of the Unified Parkinson’s Disease Rating Scale. 1 Necropsy. See footnote of Table 2.
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patients. In general, patients experienced an in-
crease in the «on» period and improvement of 
symptoms, particularly rigidity and bradykinesia, 
in the «off» period. «On» dyskinesias were re-
duced in some patients but increased in others 
(see «Complications» below). The clinical bene-
fits of the transplants, perceived either imme-
diately or around 3-6 months after the surgery, 
reached a peak at approximately 1-2 years af-
ter surgery and then progressively disappeared. 
There are, however, reports of persistent clinical 
improvements 5 to 10 years after transplanta-
tion.  In the few open studies that included con-
trols the results reported are also quite distinct. 
In the Los Angeles group study (Table 2) the 
blinded evaluation of motor benefits was higher 
in patients randomly assigned to receive more 
tissue than a control group. However, the New 
Haven group (Table 2) failed to see differences 
between transplanted patients and a control 
group of similar characteristics that received 
only pharmacological treatment. In conclusion, 
the open studies summarized in this section 
represent hallmarks in the development of cell 
therapy strategies to fight PD, although their 
scientific value is limited because of the lack of 
uniform analytical methodologies.
Clinical outcome. Double-blind studies
To progress in the evaluation of the clinical 
applicability of fetal mesencephalic cell trans-
plantation in PD, two double-blind, placebo-
controlled studies have been performed in re-
cent years. These are the first controlled phase 
III clinical trials ever done to test a cell therapy 
strategy applied to a CNS disease. The major 
methodological features of these studies are 
summarized in Table 3. Patients were subjected 
to stereotaxic bilateral implantation of fetal tis-
sue in the putamen. In the two trials a randomly 
selected placebo group was subjected to sham 
surgery consisting of craniectomy without du-
ramater perforation. Both the patients and the 
clinical evaluators were unaware of the type of 
treatment (either «placebo» or «transplant») 
applied to each case. All patients were evalua-
ted pre- and post-surgically with [18F]-dopa PET 
scans. The major objective of the studies was 
the precise evaluation of «actual» symptoma-
tic improvement of advanced PD patients after 
transplantation. The trial of the Denver/New 
York group (61) placed special emphasis on the 
effect of patient age on the clinical outcome, 
whereas the New York/Chicago/Tampa group 
(62) focused on the clinical effects of transplan-
tation of different amounts of tissue. 
In the Denver/New York trial transplanted pa-
tients showed a statistically significant improve-
ment of 18% in the UPDRS III scale in «off» with 
respect to the placebo group one year after sur-
gery. This improvement, affecting mainly rigidity 
and bradykinesia, was due to the marked effect 
of the transplants on patients below 60 years 
of age (34% average improvement). The clini-
cal benefit appeared during the first 4 months 
and was maintained in open evaluations for up 
3 years. More recent analysis of this patient co-
hort has suggested that the best prognostic fac-
tor was responsiveness to levodopa rather than 
patient’s age. Fetal cell transplantation did not 
induce significant changes in the diary of fluc-
tuations, levodopa dose or cognitive function. In 
the New York/Chicago/Tampa trial no statistica-
lly significant clinical differences in the UPDRS III 
scale in «off» were observed between patients 
of the transplanted and placebo groups two 
years after surgery. There was, however, a trend 
towards a clinical amelioration proportional to 
the amount of tissue transplanted. Patients with 
UPDRS III < 49 who received a larger amount 
of tissue showed a statistically significant clinical 
recovery with respect to the placebo controls. 
In this last subgroup, the clinical effects were 
perceived around three months after the sur-
gery and reached a peak around 6-12 months. 
There were no significant changes in the diary 
of fluctuations or the levodopa dose. 
Complications
In most of the transplantation trials done with 
fetal mesencephalic tissue, the procedure was, in 
general, well tolerated although some complica-
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tions associated with the cranial surgery were 
reported. Intracerebral hemorrhages, epileptic 
seizures, or postsurgical confusional syndromes 
were the most frequent complications, normally 
resolved after a few days of treatment. In one 
case, patient death by hydrocephaly was repor-
ted due to migration of the transplanted tissue 
to the fourth ventricle. In some patients trans-
planted with homologous fetal tissue, the ad-
ministration of immunosuppressants has been 
associated with renal dysfunction or nosoco-
mial infections. Besides these complications, the 
placebo-controlled studies have reported the 
appearance in some transplanted patients of 
severe and persistent dyskinesias (characterized 
by stereotyped abnormal movements of the 
limbs) during the «off» periods. In the Denver/
New York study this complication affected 15% 
of the patients (younger than 65 years) that had 
experienced clinical improvement.  In the New 
York/Chicago/Tampa trial, dyskinesias appeared 
in more than 50% of the patients and were par-
ticularly severe in three cases. The «off» dyski-
nesias have been suggested to originate from 
an excess of dopamine released from the trans-
plant. However, no correlation between the 
severity of the dyskinesias and the amount of 
tissue transplanted or [18F]-dopa uptake in PET 
studies (see below) has been reported. It has 
been suggested that the dyskinesias reflect the 
anomalous innervation of striatal cells by the 
transplanted neurons, however it cannot be dis-
counted that they are generated by other varia-
bles (i.e. tissue preparation) different from those 
in previous open studies. 
Neurochemical and histological data
The open trials testing the effect of fetal 
neuronal transplants have generally included 
the monitoring of striatal dopamine content 
using [18F]-dopa PET scans (see Tables 2 and 
3). Dopa (a dopamine precursor) is taken up 
by the dopamine transporter in the nigrostria-
tal presynaptic terminals (Figure 1), as well as 
in the soma and neurites of the transplanted 
dopaminergic neurons. Therefore accumula-
tion of the marker (which results in a higher 
amount of emitted radiation) provides an in-
dication of striatal dopaminergic innervation. 
Practically all the studies performed have re-
ported an increase of [18F]-dopa uptake in the 
transplanted area at one-year follow-up. In 
one study synaptic release of dopamine in the 
transplant was demonstrated by neuroimaging 
using [11]C-raclopride, a drug that competes 
with dopamine for binding to postsynaptic D2 
receptors (63). In the two double blind-studies 
[18F]-dopa uptake one year after the surgery 
was significantly higher in the transplanted pa-
tients in comparison with the placebo group. 
Thus, the neuroimaging data suggest that fetal 
mesencephalic grafts survive for several years 
after transplantation and remain neurochemi-
cally and functionally active. 
In patients that died during the studies (gene-
rally for causes not related to the transplantation 
procedure) and were subjected to necropsy, the 
direct histological examination of the striatum 
normally confirmed the in vivo PET data. The-
se postmortem histological analyses have also 
demonstrated that the surviving dopaminergic 
neurons account for less than 5% of the several 
hundreds or millions initially transplanted, which 
suggests a marked mortality of donor cells du-
ring the transplantation procedure. 
Current status of the methodology  
and future developments 
After almost 20 years of intense research, 
the applicability of fetal mesencephalic tissue 
for treatment of advanced PD is being se-
riously questioned. Besides the limitations of 
this methodology already recognized in the 
open studies (scarcity of donor tissue and poor 
cell viability), the double-blind studies have sug-
gested that the successful implantation of do-
paminergic cells in the striatum is not sufficient 
to induce significant clinical amelioration of 
symptoms. The scarcity of donor tissue (seve-
ral fetuses per patient) is heightened by ethical 
and legal concerns regarding the use of human 
embryonic material. Additionally, the dissection 
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and manipulation of fetal mesencephalic tissue 
is technically difficult and results in a mixture 
of different neural populations with a high in-
cidence of cell death. The numerous attempts 
to minimize these limitations have included the 
treatment of cells with neurotrophic factors 
or antioxidants as well as the use of porcine 
mesencephalic tissue. Although both appro-
aches have been tested in experimental animal 
models as well as in open clinical studies with 
some positive results, they have not provided 
clear improvement with respect to the trials 
utilizing human tissue. Porcine xenographs (40) 
have been virtually abandoned because of the 
danger of interspecies infections, although a 
phase III clinical trial is in progress.
A major limitation of fetal mesencephalic tis-
sue transplantation is the relatively poor clinical 
effect of this procedure despite the fact that the 
grafted dopaminergic cells remain neurochemi-
cally active. Therefore, it seems that the de novo 
formation of an ectopic SN in the striatum (the 
result of intrastriatal dopaminergic neuronal 
grafts) is not sufficient to ameliorate PD patient 
symptoms. In contrast, it seems that an excess 
of dopamine or the establishment of aberrant 
synaptic connections between the transplanted 
cells and striatal neurons, might lead to severe 
motor complications that, in terms of patient’s 
life quality can be even worse than the manifes-
tation of the disease. 
The limitations and complications derived 
from the use of fetal mesencephalic tissue have 
led to the conclusion that, in its current state, 
this procedure, although conceptually pionee-
ring in the field, is not an advisable therapeutic 
option for PD. Moreover, the double-blind pla-
cebo-controlled studies on fetal mesencepha-
lic transplantation suggest that dopamine cell 
replacement in the striatum is not the ideal 
approach to compensate for the progressive 
nigrostriatal neuronal loss. Given this scenario, 
the clinical applicability of other transplantation 
procedures based on a similar rationale (e.g., 
intrastriatal grafting of porcine mesencepha-
lic neurons or stem cell-derived dopaminer-
gic neurons) is, for the moment, uncertain. It 
is generally believed that other cell types and 
methodologies, capable of delivering locally 
the proper cocktail of trophic factors, might be 
more effective in protecting the dopaminergic 
nigrostriatal neurons from whatever insults 
cause PD and to arrest or even reverse the 
neurodegenerative process. 
Recent pilot studies with other tissues 
In recent years there have been numerous 
attempts to evaluate the potential applicability 
of dopamine-producing cells other than fetal 
mesencephalic neurons for transplantation in 
PD. In the context of this chapter the studies 
done with carotid body (CB) and retinal cells 
are particularly relevant since they have been 
transferred from animal models to PD patients. 
Transplantation of carotid body tissue
As described above, the CB is an organ com-
posed of highly dopaminergic glomus cells who-
se efficacy for antiparkinsonian cell therapy has 
been tested in animal models of PD (15, 27). A 
priori, a major advantage of the CB with respect 
to fetal mesencephalic neurons is that the for-
mer can be used for autotransplantation since 
its unilateral surgical resection has no significant 
side effects (42), thus circumventing most of the 
limitations of fetal transplants. Intrastriatal CB 
grafts can induce notable behavioral ameliora-
tion in parkinsonian rats and monkeys due not 
only to increase of the intrastriatal dopamine 
level but also to a trophic effect of the trans-
plant on the dopaminergic nigrostriatal neurons 
(28). In fact, CB glomus cells are among those 
with the highest GDNF content in adult rodents 
(29). The favorable results in preclinical studies 
stimulated the execution of two pilot phase I/II 
open trials to test the feasibility, safety and clini-
cal efficacy of CB autotrasplantation in PD. The 
experimental protocol in these studies con-
sisted of the unilateral removal of the CB and 
the preparation of cell aggregates, which were 
bilaterally deposited at the putamen through 
a stereotaxic needle (42) (Figure 5). Typically, 
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about 150-200 aggregates, with approximately 
200 cells each, were obtained from a human CB 
and, therefore the total number of cells trans-
planted was around 15,000-20,000 on each side 
of the brain. 
In the first CB trial, 5 of 6 PD patients showed 
amelioration of the UPDRS III scale in «off» pe-
riods when blindly evaluated by an independent 
neurologist using masked video recordings (42). 
Clinical improvement was between 26-74% and 
13-52% at 6 and 12 months of follow-up, res-
pectively. The patient that did not receive any 
benefit from the implantation had a fibrous ca-
rotid body with major absence of dopaminergic 
glomus cells. In the long term a trend towards 
the presurgical clinical status was observed, 
although 3 patients still maintained a measura-
ble motor improvement (15-48%) 36 months 
after transplantation. A patient of this sub-study 
who, for technical reasons, only received cells 
in one side of the brain (although the needle 
tracts were done bilaterally), showed clinical im-
provement only in the side contralateral to the 
transplant. The clinical evolution of the patients 
in the second sub-study performed by the same 
group was essentially similar to that described 
above (64). Patients of the second sub-study 
were subjected to [18F]-dopa PET scans before 
Figura 5. Intraputaminal stereotaxic transplantation of dopaminergic cells in Parkinson disease patients. 
A) Carotid body resected from a parkinsonian patient after it was cleaned of surrounding connective 
tissue. B) Carotid body cells aggregates transplanted through a stereotaxic needle as illustrated in C. Pt, 
putamen, Cd, caudate nucleus; Th, thalamus; SNc, substantia nigra pars compacta; SNr, substantia nigra 
pars reticulata. See reference (42) for further details.
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and 1 year after transplantation. This neuroche-
mical analysis showed a non-significant 5% in-
crease in mean putaminal [18F]-dopa uptake but 
there was a significant inverse relationship bet-
ween clinical amelioration and annual decline in 
putaminal [18F]-dopa uptake. Complications of 
CB grafting are similar to those reported for 
other intracerebral transplantation procedures. 
However, carotid body grafted patients, unlike 
those subjected to fetal transplantation, do not 
seem to develop off-period dyskinesias, which 
might be related to the fact that they received a 
much lower number of dopaminergic cells and 
that the main effect of CB transplants is to sti-
mulate intrinsic dopaminergic striatal reinnerva-
tion (42, 64). 
The pilot studies performed have indicated 
that CB autotransplantation is a feasible and 
safe procedure with potential clinical applicabi-
lity to treat PD patients. In addition, CB grafting 
has demonstrated similar symptomatic efficacy 
as the placebo-controlled mesencephalic grafts. 
The beneficial effect of CB grafts is higher in 
young patients with a well-preserved CB and 
in individuals with a less severe disease. Altoge-
ther, these studies suggest that the clinical im-
provement observed after CB transplantation, 
although modest, derive from a true neuropro-
tective effect of the transplanted glomus cells on 
the nigrostriatal pathway.  Nevertheless, at pre-
sent, CB autotransplantation is not a methodo-
logy ready to be evaluated in large controlled 
phase III trials until the characteristics of suitable 
candidates and the objectives of the therapy 
are clearly defined, and the origin and quanti-
ty of donor tissue are determined.  Although 
autotransplantation is conceptually attractive, 
the amount of tissue obtained from a single CB 
appears to be smaller than that needed to ob-
tain significant clinical benefit consistently. The in 
vitro expansion of CB tissue using either con-
ditionally immortalized glomus cells or their di-
fferentiation from multipotent precursors (35c), 
provides possible therapeutic strategies that will 
surely be explored in future work.   
Transplantation of retinal cells 
The retinal pigment epithelium contains do-
paminergic cells whose suitability for transplan-
tation studies has recently been tested in animal 
models of PD (26, 41). Good results in precli-
nical experiments led to the execution of an 
open pilot study in six patients with advanced 
PD. About 300,000 human pigment cells atta-
ched to gelatine microcarriers were grafted, wi-
thout immunosuppression, into the most affec-
ted putamen of each patient. All subjects were 
reported to have a clear improvement in the 
UPDRS III motor scale in «off» periods that was 
initiated during the first month of the surgery 
and improved subsequently. Average reduction 
of the UPDRS III score with respect to the basal 
value was 48%  at 12 months. No major compli-
cations or dyskinesias have been reported (65). 
Therefore, allografts of retinal pigment epithe-
lial cells seem to be well tolerated and clinically 
effective in PD patients. The mechanism of ac-
tion of these transplants is unknown, although a 
recent study has proposed that, as for CB cells, 
retinal cells could also release trophic factors 
to support nigrostriatal neurons (66). This me-
thodology is being evaluated in a double blind, 
placebo-controlled study currently in progress 
(Table 1). 
Administration of trophic fac-
tors (GDNF delivery)
Neurotrophic factors are substances (gene-
rally proteins or peptides) that, among other 
functions, regulate the differentiation and main-
tenance of neuronal phenotype. These factors 
also protect neurons against cell death by apop-
tosis and/or exogenous pathological insults. 
Numerous studies both in vivo and in vitro have 
shown that mesencephalic dopaminergic neu-
rons are sensitive to a variety of trophic factors 
including the glial cell line-derived neurotrophic 
factor (GDNF), brain-derived neurotrophic fac-
tor, neurotrophin 4, insulin-like growth factor, 
fibroblast growth factor and platelet-derived 
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growth factor, among others.  GDNF has con-
sistently shown to exert the strongest and most 
selective in vitro and in vivo trophic actions on 
nigrostriatal dopaminergic cells (67). In animal 
models of PD, GDNF can prevent neuronal de-
generation and restore the striatal dopaminer-
gic function (19b, 68-70). Depletion of GDNF 
has been found in the SN of human PD brains, 
which may constitute an additional pathogenic 
mechanism of the disease.
Although all the precedents summarized in 
the previous paragraph suggest that GDNF ad-
ministration might be a valuable neuroprotec-
tive and neurorestorative therapy for PD, the 
method of GDNF delivery into the striatum has 
become a critical issue, since GDNF does not 
cross the blood-brain barrier, diffuses poorly in 
the extracellular environment and is easily des-
troyed by proteases. Different methods of direct 
administration have been experimentally tested, 
including intermittent injections, continuous 
infusion, and implantation of GDNF-releasing 
biodegradable microspheres (71). Intraventri-
cular or intraputaminal GDNF administration 
has been reported to promote structural and 
functional recovery in advanced parkinsonian 
monkeys (70). However, in a controlled clinical 
trial, monthly intraventricular administration of 
GDNF failed to provide clinical benefit in ad-
vanced PD patients but resulted in frequent ad-
verse events (72). A post-mortem examination 
in one patient suggested that GDNF did not 
reach the target cells via this route. The safety 
and clinical effects of a continuous intraputami-
nal GDNF infusion have been evaluated in two 
open-label trials. An initial trial of a British group 
on five PD patients reported encouraging clini-
cal outcomes at one year, while [18F]-dopa PET 
studies showed an increase in putaminal uptake 
around the tip of each catheter (73). A second 
American study on 10 patients using a different 
delivery protocol also reported positive results 
at six months (74). However, a randomized pla-
cebo-controlled trial involving 34 PD patients 
showed no significant clinical differences bet-
ween groups at six months, despite increased 
[18F]-dopa uptake in the recombinant GDNF-
treated group (75). The open-label extension of 
this study was halted due to safety concerns: 
three patients developed neutralizing antibo-
dies, which could potentially cross-react with 
endogenous GDNF, while in a parallel toxico-
logy study some monkeys developed cerebellar 
damage.
In this context, research interest has focused 
on other indirect methods of GDNF delivery, 
such as cell therapy, i.e. the intrastriatal grafting 
of GDNF-producing cells (CB or genetically 
modified cells), and in vivo gene therapy using 
GDNF-encoding viral vectors (71). CB cells 
have already been tested in PD patients with 
good results in less-affected and younger pa-
tients, this finding being compatible with the tro-
phic action of the grafted tissue. Besides GDNF, 
CB glomus cells also produce BDNF and other 
factors, so they could supply damaged neurons 
with the appropriate cocktail of trophic factors 
to encourage nigrostriatal regeneration. Despi-
te these stimulating results, the use of CB or 
other cell types to deliver trophic factors in PD 
patients is still under debate and experimental 
evaluation. 
Cell therapy in other CNS 
disorders 
Huntington’s disease
Huntington’s disease (HD) is a dominantly 
inherited neurodegenerative disorder caused 
by a polyglutamine expansion in the gene en-
coding the huntingtin protein. Its pathological 
hallmark is the preferential loss of medium 
size spiny GABAergic neurons in the striatum, 
although degeneration progressively extends to 
the cortex and other brain regions. The function 
of huntingtin is unknown and the pathogenesis 
of HD remains obscure. The disease is clinically 
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characterized by movement disorders (mainly 
chorea), dementia and behavioral disturbances, 
leading to progressive disability and death. The 
relatively selective striatal damage at early sta-
ges of HD made this disease a potential target 
for cell therapy shortly after the initial experi-
mental work on PD. Animal (normally rodents) 
models of HD are obtained by striatal neural 
death-induction either with excitotoxic drugs or 
after metabolic poisoning. There also transgenic 
mouse models of HD expressing poliglutamine 
repeat expansions.  Numerous preclinical stu-
dies have demonstrated that transplants of fe-
tal striatal cells survive in the host striatum and 
induce reversion of the motor and behavioral 
abnormalities. More recently, other donor tis-
sues, such as neural progenitor cells, pre-diffe-
rentiated GABAergic neurons obtained from a 
neural stem cell line, or several types of trophic 
factor-producing cells, have also been assayed in 
rodent HD models (76).
Transplantation of human fetal striatal tissue 
has been undertaken in a few open clinical trials 
each involving each 4-7 mild to moderate HD 
patients. A Core Assessment Program for In-
tracerebral Transplantation in HD (CAPIT-HD) 
has been developed in order to standardize 
the study protocols. Some bilaterally transplan-
ted patients had small improvements in clinical 
measures at one-year, which correlated with an 
increase in the striatal and cortical metabolic 
activity measured by PET. One autopsy study 
performed 18 months after transplantation de-
monstrated surviving grafted cells innervated by 
host-derived dopaminergic fibers (77). However, 
in the long-term follow-up, a progressive clinical 
and PET decline has been consistently observed 
(78). Porcine xenografts have also been tried in 
12 HD patients, with no change in functional 
capacity one year after unilateral transplantation 
(79). Although improvements in transplantation 
procedures and patient selection could lead to 
better outcomes, striatal cell replacement alone 
seems unlikely to induce a long-lasting benefit 
taking into account the progressive and exten-
sive nature of neurodegeneration in HD. In this 
context, other strategies aiming to exert a neu-
roprotective effect on damaged neurons should 
be further developed.
Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a de-
vastating disease characterized by progressive 
upper (cortical) and lower (spinal) motor neu-
ron degeneration. The absence of disease-modi-
fying therapies has prompted experimental and 
clinical research on cell therapy. Although the 
etiopathogeny of ALS is unknown it seems that 
alteration of redox regulation both in neurons 
and astrocytes is a major cause of the disease. 
In a minority of cases the disease is familial due 
to a mutation (G93A) in the Cu-Zn superoxide 
dismutase (SOD1), and overexpression of the 
mutant human SOD1 in transgenic mice results 
in a syndrome that resembles human ALS. Using 
this animal model, several cell-replacement and/
or neuroprotective strategies have been tested 
(80). Potential benefits have been advocated 
after transplantation into the spinal cord of 
hNT cells (derived from a human teratocarci-
noma cell line), bone marrow cells, Sertoli cells, 
neural precursor cells, astrocytes derived from 
embryonic stem cells, or different genetically 
modified cells to produce trophic factors. Intra-
venous administration of human umbilical cord 
blood mononuclear cells has also been tried in 
rodents with promising results.
Some cell therapy strategies have been assa-
yed on ALS patients in small phase I-II clinical 
trials: twelve subjects were subjected to intra-
thecal implantation of encapsulated genetically 
engineered baby hamster kidney cells releasing 
human ciliary neurotrophic factor (81), and se-
ven patients participated in a study on intraspinal 
cord implantation of autologous mesenchymal 
stem cells (82). Although preliminary results of 
the later study might be encouraging, the wides-
pread nature of cell death in ALS (involving the 
spinal cord, brainstem and cortex) is a daunting 
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challenge for focal cell replacement strategies. 
On the other hand, diffuse trophic factor deli-
very from glial cells or combined approaches 
(cell replacement plus growth factor delivery) 
may show promise in modifying the course of 
the disease. 
Currently, numerous cell-based therapies for 
ALS are being performed in institutions outsi-
de the academic environment without sufficient 
scientific knowledge or medical control. The cli-
nical outcome of these operations is not well 
documented and therefore there is urgent need 
of phase III (double-blind and placebo-contro-
lled) studies to clarify the actual efficacy of cell 
therapy in ALS. 
Spinal cord injury
In recent years cell-based therapies have 
been intensely studied to ascertain whether 
they exert favorable effects on traumatic spinal 
cord injury (SCI). Several groups have repor-
ted excellent results in animal models and some 
pilot clinical studies are being performed.  The 
experimental strategies designed for cell thera-
py in SCI vary depending on the nature of the 
lesion (complete or incomplete), and whether 
the treatment is applied few hours/days (acute) 
or weeks/months (chronic) after the lesion. In 
the case of complete spinal cord lesions the ul-
timate goal is to induce neuronal regeneration, 
a challenging but as yet unreachable scenario 
that is worth pursuing since it is expected that 
a significant functional recovery could be obtai-
ned even if only 1% of the severed axons are 
replaced or regenerated. In incomplete spinal 
cord lesions the functional failure is derived in 
part from axons partially damaged by contu-
sion, edema, or ischemia. In these cases neuro-
protective measures can help to obtain axonal 
re-myelinization and sprouting.
A variety of cell types tested in animal models 
of SCI have shown considerable therapeutic 
potential after intraspinal transplantation or fo-
llowing administration by other routes, such as 
intravascular, intraventricular or intrathecal (83). 
Schwann cells have been transplanted into spi-
nal cord animal models based on the regene-
rative capacity of this cell type observed in the 
peripheral nervous system. Similarly, olfactory 
ensheathing glia, a specialized form of glial cell 
able to promote regeneration of axons in the 
olfactory nerve, have been tested, with some 
success, for regeneration in spinal cord injuries 
(84). Neural progenitor cells have been implan-
ted in spinal cord animal models yielding beha-
vioral recovery presumably due to neurogenesis 
and synaptogenesis from the transplanted cell 
preparation or from donor-host humoral inte-
ractions that may support regeneration of host 
axons. Most of the effects exerted by either 
neural or stem cell-derived progenitors appear 
to be due to their preferential differentiation 
to oligodendrocytes or astrocytes. In fact oligo-
dendrocytes derived from human embryonic 
stem cells have also been reported to myelinate 
axon in foci of contused spinal cords. An enti-
rely different approach relies on the capacity of 
endogenous mesenchymal or immune cells to 
provide axonal regeneration. With this objective 
appropriately activated macrophages have been 
shown to provide functional recovery.
Regarding the clinical application of cell the-
rapy in SCI, several small phase I-II pilot studies 
using various cells types have shown promising 
but inconclusive results. Twenty patients with 
acute (n = 7) or chronic (n = 13) SCI recei-
ved autologous bone marrow transplantation 
by intra-arterial (via catheterization of a. ver-
tebralis) or intravenous route, with promising 
results in the acute phase (up to 1 month after 
injury) (85). Eight patients were subjected to 
intraspinal injection of incubated autologous 
macrophages within 14 days of injury, three 
of whom achieved neurological improvement 
(86). For the purpose of clinical applicability 
a number of groups have demonstrated the 
production of olfactory ensheathing glial cells 
(OECs) by tissue culture of the olfactory epi-
thelium obtained from biopsy samples of the 
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upper nasal lining. Others have used OECs 
obtained from fetuses or cadavers. An initial 
published clinical trial has shown no adverse 
effects one year after transplanting autologous 
cultured mucosal OECs into spinal injuries 
(87). Two other neurosurgical teams (one in 
Beijing and another in Lisbon), have adopted 
transplantation of olfactory tissue as a clinical 
procedure for treating patients with SCI. The 
results from these groups are uncertain, not 
well documented, and criticized by part of the 
scientific community (84, 88). Apart from press 
commentaries, no real breakthroughs in clini-
cal achievements have been proved. Therefore, 
validation of these and other procedures must 
await the outcomes of independent randomi-
zed double-blind controlled trials that will su-
rely be performed in the near future.  
Stroke
Among neurological disorders, stroke re-
presents a leading cause of death and disabi-
lity in developed countries and despite inten-
se research only a few options exist for the 
treatment of stroke-related infarction of brain 
tissue.  Numerous preclinical experimental stu-
dies on cell therapy have been performed in 
rodent models of stroke (endothelin-induced 
transient middle cerebral artery occlusion or 
collagenase-induced intracerebral hemorrha-
ge), which include direct grafting of cells in the 
infarcted area or surroundings as well as intra-
ventricular, subarachnoidal, intra-arterial or in-
travenous cell administration. Among the cells 
tested are adult stem cells from bone marrow, 
umbilical cord and neural or adipose tissue, 
as well as embryonic stem cell-derived neu-
ral (neurons and glial) cells. Some studies have 
used engineered neural stem cells to produce 
angiogenic factors (VEGF and others) as well 
as the GDNF-secreting CB cells. In experimen-
tal stroke, cell therapy can partly reverse some 
behavioral deficits. However, the underlying 
mechanisms remain unknown as most studies 
reveal little, if any, evidence for neuronal repla-
cement and the observed behavioral improve-
ments appeared to be related more to a graft-
derived induction of a positive response in the 
remaining host tissue than to cell replacement 
by the graft itself (89-91).
From a clinical standpoint the information 
available pertains only to a few pilot studies 
performed on a small patient cohort. The group 
of Pittsburgh pioneered the clinical application 
of cell therapy for stroke by performing stereo-
taxic implantation of human neuronal cell lines 
with promising results. However, a controlled 
randomized trial by the same group in patients 
with ischemic or hemorrhagic subcortical mo-
tor strokes (treatment n = 14; control n = 4) 
failed to show significant benefit in the primary 
outcome measure (92).  A study based on trans-
plantation of fetal porcine cells was terminated 
by the USA Food and Drug Administration 
after the inclusion of five patients. Autologous 
mesenchymal stem cell transplantation by intra-
venous infusion, which appear to migrate to the 
site of the lesion, has also been tested in some 
clinical trials.  One of the most representative 
studies is that performed by Bang et al. (93) on 
five stroke patients and 25 controls. In this trial 
the treated group achieved a better functional 
outcome at six months compared with controls. 
As indicated above, both the mechanisms of ac-
tion of transplanted cells and their actual clinical 
efficacy are still undetermined. Cell therapy in 
stroke is a promising experimental approach 
but for the moment not a realistic therapeutic 
option. 
Other diseases
Besides the preclinical and clinical studies 
already discussed, cell-based neuroregenerati-
ve or protective therapies have been assayed 
in several other neurological disorders. Neural 
precursor cell transplantation has been shown 
to attenuate the severity of experimental au-
toimmune encephalomyelitis, an animal model 
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of multiple sclerosis. Intraventricular transplan-
ted cells migrated along white matter tracts and 
seemed to down-regulate the acute inflamma-
tory process and reduce axonal injury (94). A 
different procedure, autologous hematopoie-
tic stem cell transplantation, has been used to 
treat patients with severe multiple sclerosis. In 
a series of 178 patients, 63% were reported to 
have neurological improvement or stabilization 
at a median of 41.7 months after transplanta-
tion (95). However, a recent autopsy study on 
five patients who received this transplant found 
evidence for ongoing demyelination and neuro-
degeneration.
Hematopoietic stem cell transplantation, in-
cluding umbilical cord blood transplantation, is 
being currently under consideration as a pos-
sible therapy in young patients with storage 
diseases such as mucopolysaccharidosis, muco-
lipidosis, leukodystrophies, Krabbe disease, Tay-
Sachs disease or neuronal ceroid lipofuscinosis. 
Intracranial transplantation of neural stem cells 
has recently shown striking beneficial effects in a 
mouse model of Sandhoff disease, a lethal gan-
gliosidosis (96). However, further basic research 
in these areas is needed before the experimen-
tal data warrant the translation to patients of 
safe procedures with reasonable and well-de-
monstrated clinical efficacy. 
Conclusions  
and perspectives
Although neuroregeneration and neurorepair 
are concepts and goals intimately associated with 
the development of modern neuroscience, it is 
only in the last 25 years that experimental and 
clinical studies have systematically addressed the 
possibility of neural reparation by means of cell 
therapy. Diseases of the brain and spinal cord 
represent especially daunting challenges for cell-
based strategies of repair, given the multiplicity 
of cell types within the adult central nervous 
system, and the precision with which they must 
interact in both space and time. Nonetheless, a 
number of diseases are, in principle, especially 
appropriate for cell-based therapy, in particular 
those in which single phenotypes are lost, and in 
which the re-establishment of vectorially speci-
fic connections is not entirely requisite for the-
rapeutic benefit. In recent years, the preclinical 
and clinical studies on Parkinson’s disease initia-
ted in the 1980s have been extended to other 
neurological diseases, such as Huntington’s di-
sease, amyotrophic lateral sclerosis, stroke, and 
spinal cord injury, among others. 
Originally, the goal of cell therapy was the 
restoration of function by replacement of dead 
cells with healthy ones. However, in most recent 
studies the primary interest has shifted from cell 
replacement to neuroprotection, in the hope 
that application of the proper cocktail of trophic 
factors released from cells grafted at the injured 
sites or administered systemically would either 
prevent neuronal damage or activate intrinsic 
regenerative mechanisms leading to restoration 
of the destroyed neurons or synaptic connec-
tions. The discovery of neurogenic centers in 
the adult brain (in the subventricular zone of the 
lateral ventricles and the dentate gyrus of the 
hippocampus) has stimulated research on the 
potential therapeutic applicability of pre-existing 
neuronal precursors, which under appropriate 
conditions could migrate and differentiate to 
replace destroyed cells in other parts of the 
brain. This possibility is, however, speculative and 
only based on preliminary experimental ob-
servations. Recently, much attention has been 
focused on the relevance of hippocampal neu-
rogenesis to the pathophysiology and treatment 
of mood disorders. Indeed all major pharmaco-
logical and non-pharmacological treatments for 
depression enhance hippocampal neurogenesis 
and suppressing hippocampal neurogenesis in 
mice blocks behavioral responses in some anti-
depressant-sensitive tests.
Neurologic cell-based therapies have been 
also much influenced by the development of 
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embryonic stem (ES) cell research, as these cells 
have the potential to give rise in vitro to any cell 
type of the adult organism.  ES or iPS cells are 
generally thought to offer a promising source of 
neurons suitable for cell replacement therapy in 
Parkinson’s disease and other disorders. Most 
investigators in the field are, however, aware 
that translation of ES/iPS cells to the clinical 
setting is confronted with numerous limitations 
and unsolved problems. Differentiation of ES/
iPS cells to mature neurons is still not well con-
trolled and therefore the possibility of tumor 
generation is high. In addition, the short lasting 
viability of neurons derived from human ES(iPS 
cells compromises their use in cell therapy. ES/
iPS cell-derived neuronal types may not possess 
the complete set of phenotypic features of their 
in vivo counterparts, which may contribute to 
the limited success of these cells in repairing 
injured or diseased brain and spinal cord in ani-
mal models. Hence, efficient generation of neu-
ral subtypes with correct phenotype remains a 
challenge. Consequently, major hurdles still lie 
ahead in applying human ES/iPS cell-derived 
neural cells clinically.
Although cell therapy constitutes an actively 
progressing research field, it is also the subject 
of numerous criticisms and concerns. The scien-
tific and technical advances being made are qui-
te heterogeneous and erratic, as in many cases 
transplantation studies are performed without a 
precise knowledge of the putative therapeutic 
products released by the cells, their mechanisms 
of action, or even the type of cell transplanted. 
Moreover, together with well-controlled pilot 
clinical trials being performed in academic re-
search environments, there are institutions offe-
ring cell-based therapies to heavily deteriorated 
patients without having performed the neces-
sary scientific preclinical studies and methodo-
logical (safety and feasibility) tests. In conclusion, 
neurologic cell-based therapies still remain a 
promise rather that a reality, and effective clinical 
translation in this area will necessarily require a 
period of sustained and solid basic research.    
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